Close
Hub paper published in Cancer Gene Therapy Nature
17 February 2020
Lead author Dr Maria Papathanasiou (pictured here with Professor Suzanne Farid) and the Future Targeted Healthcare Manufacturing Hub team have published a paper presenting novel solutions to existing manufacturing and distribution challenges
Maria and her colleagues believe the technique will facilitate the scale-up of autologous CAR-T cell therapy and bring down the cost of treatment. You can read the full article "Autologous CAR T-cell therapies supply chain: challenges and opportunities?" here
The Hub is a based in UCL Biochemical Engineering with spokes comprising researchers from Imperial College London and several other UK universities, along with a user group of manufacturers, who are working to address challenges within medicine manufacturing, business and regulatory frameworks to make medicines cheaper and more widely available to patients.
Dr Papathanasiou explained: “Every aspect of this process needs to be carefully planned for it to operate on a larger scale, from storage facilities in clinical and manufacturing settings to the use of cloud-based platforms for tracking samples across their journey.”